Market Overview

UPDATE: Morgan Stanley Initiates Alnylam Pharmaceuticals at Overweight on Positively Viewed Amyloidosis Program


In a report published on Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with an Overweight rating and a price target of $35.

In the report, Morgan Stanley stated, "We view Alnylam as the leader in RNAi drug development. The components of this technology platform (i.e. drug delivery, drug composition, target selection) have progressed to the point where we have high confidence in the ability to move from a science based company to a commercial one."

Alnylam Pharmaceuticals closed on Monday at $30.75.

Latest Ratings for ALNY

Nov 2020Morgan StanleyMaintainsOverweight
Nov 2020SVB LeerinkMaintainsMarket Perform
Nov 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings


Related Articles (ALNY)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Initiation Analyst Ratings

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at